Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma
Public ClinicalTrials.gov record NCT02856568. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib, Open-Label, Dose- Escalation Trial of ACY-1215 in Combination With Gemcitabine and Cisplatin in Patients With Unresectable or Metastatic Cholangiocarcinoma
Study identification
- NCT ID
- NCT02856568
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Mayo Clinic
- Other
- Enrollment
- Not listed
Conditions and interventions
Conditions
- Non-Resectable Cholangiocarcinoma
- Recurrent Cholangiocarcinoma
- Stage III Extrahepatic Bile Duct Cancer
- Stage III Intrahepatic Cholangiocarcinoma
- Stage IIIA Hilar Cholangiocarcinoma
- Stage IIIB Hilar Cholangiocarcinoma
- Stage IVA Extrahepatic Bile Duct Cancer
- Stage IVA Hilar Cholangiocarcinoma
- Stage IVA Intrahepatic Cholangiocarcinoma
- Stage IVB Extrahepatic Bile Duct Cancer
- Stage IVB Hilar Cholangiocarcinoma
- Stage IVB Intrahepatic Cholangiocarcinoma
- Unresectable Extrahepatic Bile Duct Carcinoma
Interventions
- Cisplatin Drug
- Gemcitabine Hydrochloride Drug
- Laboratory Biomarker Analysis Other
- Pharmacological Study Other
- Ricolinostat Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2017
- Primary completion
- Sep 30, 2021
- Completion
- Sep 30, 2021
- Last update posted
- May 29, 2017
2017 – 2021
United States locations
- U.S. sites
- 3
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Arizona | Scottsdale | Arizona | 85259 | — |
| Mayo Clinic in Florida | Jacksonville | Florida | 32224-9980 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02856568, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 29, 2017 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02856568 live on ClinicalTrials.gov.